Business
ALGAE DYNAMICS CORP Announces Research Agreement With University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer
ALGAE DYNAMICS CORP Announces Research Agreement With University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer.
About this update from Canaquest Medical Corporation
[{"type":"text","content":"\n \n \n ALGAE DYNAMICS CORP Announces Research Agreement With University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer\n \n \nALGAE DYNAMICS CORP Announces Research Agreement With University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer\n \n TORONTO, ON--(Marketwired - Feb 24, 2017) - ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the \"Company\"), a development stage company focused on the commercialization of its proprietary BioSilo® cultivation and extraction system for the growth of algae strains for use in the food and health supplement industry, today announced a research agreement with the University of Waterloo to perform fundamental research on cannabis oil and its constituents in the context of the development and treatment of cancers of the colorectum, pancreas, breast and prostate. The Sponsored Research Agreement is entitled \"Studies on botanical oils from Algae Dynamics\".\n This announcement follows the Company's previously announced new strategic initiative to explore the extraction of oils from other botanicals, most notably cannabis, and to seek product development and formulation opportunities that combine the benefits of algae and cannabis oils. This research agreement will directly support this initiative and will \"carry out studies relating to the cellular safety and known cancer-related potential of components\" within botanical oils, with a focus on cannabis. \n Paul Ramsay, Chairman and President of the Company said, \"With this research agreement, we are building upon the previously announced strategic initiative into the use of extracts from cannabis oil, in conjunction with algae oil, to develop unique health products and formulations. In our previous press release, we outlined a three-part approach, the first being Research and Development work with Canadian universities. This is the first of such research agreements relating to the use of botanical extracts including cannabinoids that we expect to employ\".\n The investigator leading the research is Dr. Jonathan Blay, a professor and researcher in the School of Pharmacy at the University of Waterloo. Dr. Blay has an extensive background in cancer research and the fostering of novel areas of cancer research in Canada. Dr. Blay's main research focus is in understanding the tumor microenvironment of soli...